[Form 4] Lixte Biotechnology Holdings, Inc. Warrants Insider Trading Activity

Rhea-AI Filing Summary

Michael Andrew Holloway was appointed to the board of Lixte Biotechnology Holdings, Inc. and on August 15, 2025 was granted options to purchase 25,000 shares of common stock at an exercise price of $3.59 per share. The options vest 50% immediately on the effective date and the remaining 50% vests in increments of 12.5% on December 31, 2025 and on the last day of each subsequent calendar quarter until fully vested. The options are exercisable beginning August 15, 2025 and expire on August 15, 2030. The Form 4 was signed by Mr. Holloway on August 18, 2025.

Positive

• Options granted in connection with board appointment, aligning executive incentives with shareholder interests
• Immediate 50% vesting provides immediate alignment while remaining vesting ties compensation to continued service
• Clear disclosure of terms including exercise price ($3.59), vesting schedule, exercisable and expiration dates

Negative

• Potential dilution from 25,000 options (magnitude unspecified because total shares outstanding not provided)
• No information provided in this filing about aggregate insider holdings or whether the grant is from existing plan shares or increases authorized equity

Insights

Financial Analyst

TL;DR: Director appointment accompanied by a standard option grant; modest in size and typical for board compensation.

The grant of 25,000 options at a $3.59 exercise price upon appointment is a routine equity-based board compensation event. The immediate 50% vesting aligns the director’s initial equity stake with service commencement, while the remaining vesting schedule ties further value to continued service through quarterly vesting until fully vested. The five-year term to 08/15/2030 is typical for director option grants. The grant size should be viewed relative to total outstanding shares (not provided here) to assess dilution impact.

Corporate Governance Expert

TL;DR: Governance action: board appointment with customary option award and service-based vesting; no red flags in disclosure.

The disclosure clearly states the connection between the grant and the board appointment and provides a specific vesting schedule and exercise price. The filing indicates direct ownership and includes a manual signature dated 08/18/2025. There is no indication of accelerated vesting beyond described terms or of related-party conflicts disclosed in this Form 4. Additional context such as aggregate insider holdings or equity plan limits is not provided in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Holloway Michael Andrew

(Last) (First) (Middle)

680 E. COLORADO BLVD., SUITE 180

(Street)

PASADENA CA 91101

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LIXTE BIOTECHNOLOGY HOLDINGS, INC. [ LIXT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to Purchase Common Stock	$3.59	08/15/2025		A		25,000		08/15/2025	08/15/2030	Common	25,000	$0(1)	25,000	D

Explanation of Responses:

1. Effective August 15, 2025, the reporting person was granted stock options to purchase 25,000 shares vesting 50% on the effective date, the remaining 50% vesting 12.5% on December 31, 2025 and on the last day of each subsequent calendar quarter until fully vested, subject to continuous service. The grant was in connection with the reporting person being appointed to the Company's Board of Directors. The exercise price is $3.59 per share.

	/s/ Michael Holloway	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 4 filed for LIXTW disclose about Michael Holloway's transaction?

The Form 4 discloses that Mr. Holloway was granted options to purchase 25,000 shares at an exercise price of $3.59 on 08/15/2025, with 50% vesting immediately and the remainder vesting quarterly until fully vested.

When do the options expire and when are they exercisable for LIXTW?

The options are exercisable beginning 08/15/2025 and expire on 08/15/2030.

What is the vesting schedule for the options reported in the LIXTW Form 4?

Vesting: 50% on the effective date (08/15/2025); the remaining 50% vests 12.5% on 12/31/2025 and on the last day of each subsequent calendar quarter until fully vested, subject to continuous service.

Was the option grant tied to a specific corporate event in the filing?

Yes. The filing states the grant was made in connection with Mr. Holloway being appointed to the Company’s Board of Directors.

Who signed the Form 4 and when was it signed?

Michael Holloway signed the Form 4 on 08/18/2025.